FENNEC PHARMACEUTICALS INC. Adjustments to Additional Paid in Capital, Warrant Issued
FENNEC PHARMACEUTICALS INC. (FENC) reported Adjustments to Additional Paid in Capital, Warrant Issued of $441.00 thousand for the 12-month period ending 2022-12-31, per its 10-K filed 2024-03-29.
Discontinued › Shareholders' Equity › Adjustments to Additional Paid in Capital
us-gaap:AdjustmentsToAdditionalPaidInCapitalWarrantIssued · last filed 2024-03-29
- FENNEC PHARMACEUTICALS INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2022-09-30 was $441.00K.
- FENNEC PHARMACEUTICALS INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2019-03-31 was $255.00K.
- FENNEC PHARMACEUTICALS INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2016-12-31 was $23.00K.
- FENNEC PHARMACEUTICALS INC. adjustments to additional paid in capital, warrant issued for the quarter ending 2016-09-30 was $19.00K.
- FENNEC PHARMACEUTICALS INC. adjustments to additional paid in capital, warrant issued for fiscal 2022 was $441.00K.
- FENNEC PHARMACEUTICALS INC. adjustments to additional paid in capital, warrant issued for fiscal 2019 was $255.00K.
- FENNEC PHARMACEUTICALS INC. adjustments to additional paid in capital, warrant issued for fiscal 2017 was $0.00, a 100.00% decline from fiscal 2016.
- FENNEC PHARMACEUTICALS INC. adjustments to additional paid in capital, warrant issued for fiscal 2016 was $72.00K.
| Period end | Adjustments to Additional Paid in Capital, Warrant Issued 3 month | Adjustments to Additional Paid in Capital, Warrant Issued 6 month | Adjustments to Additional Paid in Capital, Warrant Issued 9 month | Adjustments to Additional Paid in Capital, Warrant Issued 12 month |
|---|---|---|---|---|
| 2022-12-31 | $441.00K 10-K · filed 2024-03-29 | |||
| 2022-09-30 | $441.00K 10-Q · filed 2023-11-09 | |||
| 2019-12-31 | $255.00K 10-K · filed 2021-03-30 | |||
| 2019-03-31 | $255.00K 10-Q · filed 2020-05-14 | |||
| 2017-12-31 | $0.00 10-K · filed 2018-03-28 | |||
| 2016-12-31 | $23.00K 10-Q · filed 2017-05-12 | $42.00K derived: sum of 2 quarters · filed 2017-05-12 | $59.00K derived: sum of 3 quarters · filed 2017-05-12 | $72.00K 10-K · filed 2018-03-28 |
| 2016-09-30 | $19.00K 10-Q · filed 2017-05-12 | $36.00K derived: sum of 2 quarters · filed 2017-05-12 | $49.00K derived: sum of 3 quarters · filed 2017-05-12 | |
| 2016-06-30 | $17.00K 10-Q · filed 2017-05-12 | $30.00K derived: sum of 2 quarters · filed 2017-05-12 | ||
| 2016-03-31 | $13.00K 10-Q · filed 2017-05-12 | |||
| 2003-06-30 | $53.00K 10-Q · filed 2013-11-18 | |||
| 2000-06-30 | $255.00K 10-Q · filed 2013-11-18 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| C4 Therapeutics, Inc. (CCCC) | United States | $0.373B | -5.65 |
| Artiva Biotherapeutics, Inc. (ARTV) | United States | $0.367B | |
| Cabaletta Bio, Inc. (CABA) | United States | $0.365B | -2.81 |
| AGENUS INC (AGEN) | United States | $0.383B | 1.41 |
| Surrozen, Inc./DE (SRZN) | United States | $0.395B | |
| Zura Bio Ltd (ZURA) | $0.398B | -6.56 | |
| Ocugen, Inc. (OCGN) | United States | $0.343B | -6.34 |
| Scribe Therapeutics, Inc. (SCTX) | United States | $0.410B | |
| Editas Medicine, Inc. (EDIT) | United States | $0.424B | -4.29 |
| Kyverna Therapeutics, Inc. (KYTX) | United States | $0.434B | -3.60 |